Physician profile
Christen Mccabe
NPI 1659983948
$11,850.86
in general payments reported to CMS, 2019-2025
27 companies · $4,264 in 2025
The $4,264 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $623 · 2022: $654 · 2023: $904 · 2024: $5,406 · 2025: $4,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,506 · Food and Beverage: $3,984 · Travel and Lodging: $1,998 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,506.25 |
| Food and Beverage | $3,984.46 |
| Travel and Lodging | $1,998.40 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $7,362.88 | 2023-2025 | Uptravi, Opsumit, Veletri |
| United Therapeutics Corporation | $687.19 | 2021-2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.61 | 2021-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals Lp | $442.37 | 2021-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $422.40 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $308.70 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $274.57 | 2023-2025 | Winrevair |
| Grifols USA, LLC | $236.45 | 2021-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $230.27 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $209.72 | 2021-2023 | Acthar |
| Mylan Specialty L.P. | $201.53 | 2021-2024 | Yupelri |
| Insmed, INC. | $138.49 | 2021-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $120.53 | 2024-2025 | Dupixent |
| Baxter Healthcare | $82.51 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Takeda Pharmaceuticals U.S.A., INC. | $69.23 | 2023-2025 | Glassia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $53.93 | 2025 | Yupelri |
| Harmony Biosciences LLC | $52.43 | 2022-2025 | Wakix |
| Inogen, INC. | $49.90 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Verona Pharma, INC. | $48.81 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $41.88 | 2025 | Sunosi |
| Amgen INC. | $32.33 | 2025 | Tezspire |
| Abbvie INC. | $29.76 | 2024 | |
| Vifor Pharma, INC. | $24.03 | 2025 | Zemaira |
| Ani Pharmaceuticals, INC. | $19.82 | 2023 | Purified Cortrophin Gel |
| Advanced Respiratory, INC | $18.29 | 2021 | |
| Pfizer INC. | $15.29 | 2024 | |
| Alexion Pharmaceuticals, INC. | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christen Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.